KPV

KPV is a short anti-inflammatory tripeptide composed of the amino acids lysine, proline, and valine. It corresponds to the C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH), the parent melanocortin peptide, and is classified as a melanocortin-derived tripeptide studied for its immunoregulatory and inflammatory-pathway research properties. Researchers comparing dose ranges often examine the larger 30 mg KPV format alongside this 10 mg presentation.

Research interest in KPV centers on its proposed ability to dampen pro-inflammatory signaling within epithelial and immune-cell models. Experimental work suggests that KPV may enter cells, translocate toward the nucleus, and interfere with NF-κB-mediated transcription, reducing the expression of inflammatory cytokines such as TNF-α, IL-1β, and IL-6. Additional research models examine its influence on mast-cell activation, neutrophil recruitment, and intestinal epithelial barrier integrity, positioning KPV as a useful tool for investigating mucosal-inflammation pathways without engaging classical melanocortin receptors. This research framework overlaps with work on respiratory-mucosa bioregulators such as Bronchogen.

Because of these properties, KPV has been investigated in research contexts focused on inflammatory bowel research models, gut-barrier biology, skin inflammatory-signaling studies, and oral and mucosal tissue research. Murine colitis studies reported that KPV exposure was associated with reduced inflammatory markers and improved epithelial recovery in research models of inflammatory bowel disease (Kannengiesser et al., 2008, Inflammatory Bowel Diseases). Comparative bioregulator research also references lung-tropic Chonluten peptide investigations for parallel mucosal-pathway studies.

The peptide is supplied as a lyophilized powder to ensure optimal stability during storage and handling.

Melanocortin peptides have long been studied for their role in pigmentation, inflammatory signaling, and immune regulation. Alpha-melanocyte-stimulating hormone (α-MSH) is the most extensively investigated member of this family and is known for potent inflammatory-pathway modulation. During the late 1990s, structure-activity research identified the C-terminal tripeptide of α-MSH, Lys-Pro-Val, as a minimal sequence that retains much of the anti-inflammatory profile of the parent hormone.

Subsequent research demonstrated that KPV exerts its activity through a melanocortin-receptor-independent mechanism. Cellular uptake studies suggested that KPV can enter epithelial and immune cells, where it appears to interfere with intracellular inflammatory signaling rather than binding extracellular receptors. This distinct mode of action has positioned KPV as a research compound of interest for investigators exploring targeted, receptor-independent inflammatory-pathway regulation.

Today, KPV is a standard research tool for studying mucosal inflammation, epithelial barrier biology, and the broader concept of small-peptide-mediated transcriptional control. Its compact size, oral and topical research-format compatibility, and clearly defined structure make it a frequent reference compound in laboratory work on inflammatory bowel research, skin biology, and immune-cell signaling.

1. NF-κB Pathway Modulation

KPV is studied as an intracellular modulator of the NF-κB inflammatory signaling cascade. Research models suggest that the tripeptide can enter cells via peptide-transporter systems such as PEPT1, accumulate in the cytoplasm, and reduce nuclear translocation of NF-κB. This in turn lowers transcription of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6 in epithelial and immune-cell models.

2. Receptor-Independent Anti-Inflammatory Activity

Unlike the parent α-MSH peptide, KPV is reported to act through a melanocortin-receptor-independent mechanism. Investigations indicate that its inflammatory-pathway effects persist in research systems lacking classical melanocortin receptors, supporting a model in which KPV interacts with intracellular targets rather than cell-surface receptors.

3. Epithelial Barrier and Mucosal Research

KPV is examined for its influence on intestinal epithelial integrity in research models of mucosal inflammation. Studies suggest reduced permeability markers, preserved tight-junction protein expression, and lower neutrophil infiltration in colitis-type research designs, supporting its use as a tool compound in gut-barrier biology.

4. Mast Cell and Immune-Cell Signaling

Experimental research has investigated KPV in relation to mast-cell degranulation, eosinophil recruitment, and macrophage cytokine output. These findings support broader interest in the peptide as a research compound for studying allergic-type, skin-inflammatory, and oral-mucosal research models.

Research Applications

Conclusion

KPV is a melanocortin-derived tripeptide investigated as a receptor-independent modulator of intracellular inflammatory signaling. By reducing NF-κB-driven cytokine expression and supporting epithelial barrier integrity in research models, it serves as a valuable research compound in laboratory studies of mucosal inflammation, gut biology, and small-peptide anti-inflammatory mechanisms.

Research Use Disclaimer

This product is intended for research and laboratory use only. It is designed exclusively for in vitro research purposes. All information provided is for educational and research reference only. This product is not intended for human or animal use. It is not a drug, food, or cosmetic and must not be marketed, labeled, or used as such. Use and handling are restricted to trained and qualified professionals.